Boehringer Ingelheim is thinking in blockbuster terms as it throws its hat into the ever-widening CD47 ring
Boehringer Ingelheim is jumping onto the CD47 “don’t-eat-me” pathway.
The German company is paying $37 million in cash and near-term milestones to grab rights to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
